New York, NY (PRWEB) July 11, 2014
As part of its morcellator lawsuit (http://www.gynecaremorcellatorlawsuit.com/) investigation, Bernstein Liebhard LLP has been closely monitoring the ongoing meeting of the U.S. Food & Drug Administration’s (FDA) Obstetrics and Gynecology Devices Panel, which has been convened to explore ways to mitigate the cancer risks associated with the use of power morcellators in minimally invasive gynecological surgeries. According to a report published by Dow Jones Business News, a number of panel members have financial relationships with medical device companies that market power morcellators. One of those individuals, Dr. Andrew Brill, removed himself from the Panel two days before the meeting began, after the FDA reviewed more than $100,000 in fees he received from Johnson & Johnson’s Ethicon, Inc. unit. At least two other gynecologists on the panel have also had financial relationships with manufacturers, according to the report.*
“This Panel will make recommendations that could have financial consequences for companies that market power morcellators. It is important to avoid even the appearance of conflicts-of-interest among its members,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating morcellator lawsuits on behalf of women who may have experienced the upstaging of uterine sarcoma and other cancers due to uterine morcellation.
Morcellator Cancer Dangers
Power morcellators are used during laparoscopic hysterectomy and fibroid removals to shred tissue in order to facilitate its removal through a small abdominal incision. The FDA meeting, which continues today in Silver Spring, Maryland, is part of the agency’s ongoing review of cancer risks associated with the devices. In April, the FDA issued an alert discouraging doctors from using the devices in minimally invasive gynecological surgeries due to the potential that they can disseminate undetected uterine cancer cells into the peritoneal cavity. According to the agency, about 1 in 350 women undergoing fibroid removal has undetected cancer cells in their fibroids, and dissemination of these cells via morcellation can greatly reduce a patient’s odds of long-term survival.
Following the issuance of the FDA alert, Ethicon announced it would suspend sales of its Gynecare Morcellex,Morcellex Sigma Tissue Morcellator System, and Gynecare X-Tract Tissue Morcellator products pending further guidance from the agency.* A number of hospitals, including the Cleveland Clinic, have also moved to ban or limit the technique until the FDA completes its review.**
Victims of uterine cancer that was allegedly spread via a power morcellator may be eligible for compensation. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLP's website. Free case reviews can also be obtained by calling 800-511-5092.
*http://www.nasdaq.com/article/doctor-quits-uterine-device-safety-panel-over-conflict-20140710-00793, Dow Jones News Service, July 10, 2014
**reuters.com/article/2014/04/30/us-johnson-johnson-device-idUSKBN0DG06G20140430, Reuters, April 30, 2014
***cleveland.com/healthfit/index.ssf/2014/04/surgical_tool_for_hysterectomy.html, Cleveland Plain Dealer, April 28, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
Read the full story at http://www.prweb.com/releases/morcellator-lawsuit/uterine-sarcoma/prweb12012324.htm.
Copyright©2014 Vocus, Inc.
All rights reserved